EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. Financials - Benzinga

EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc.

EGRXOTCEM

Trade with Public

Trade with Public

$2.14

At close: Oct 11, 5:00 PM EST

$0.3500

-1.79-83.64%

After Hours: Jan 27, 4:01 PM EST

Overview News Earnings ForecastFinancialsSentiment Ownership Compare

EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. Financials

EAGLE PHARMS INC by Eagle Pharmaceuticals, Inc. (EGRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings

Avi Kapoor

Earnings Scheduled For November 14, 2023

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.

Benzinga Insights

Eagle Pharmaceuticals's Earnings: A Preview

Benzinga Insights

PRO
Eagle Pharmaceuticals Delays Q3 2023 Results And Conference Call; Expects to File Its Form-10-Q By Nov. 14, 2023

Benzinga Newsdesk

PRO
Eagle Pharmaceuticals Reiterates Its Previously Issued Guidance For Fy23, With Adjusted EBITDA Of $78M-$84M And Adjusted EPS Of $4.40-$4.70 Versus Consensus Of $4.34

Benzinga Newsdesk

PRO
Eagle Pharmaceuticals Reiterates FY23 Adjusted EPS Guidance Of $4.40-$4.70 Vs. Consensus Of $4.34

Benzinga Newsdesk